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Abstract
Background
Previously, diabetes was a contraindication to pregnancy, and few live children were born and 
raised by  mothers with diabetes. The current situation is much different, and women with 
diabetes are no longer discouraged to get pregnant. There are however still many challenges 
found in pregnancies complicated by diabetes. Improvements have been made, but there are still a 
higher rate of pre-eclampsia, stillbirths, perinatal death and infant death amongst pregnancies 
complicated by diabetes. In addition to this, there is also a higher rate of macrosomia and 
congenital birth defects, such as cardiovascular and neural spine defects.   
The aim of this project is to look at the obstetric situation for women living with diabetes today, 
with regard to the kind of preparations that have to be made prior to conception,  major health 
risks during pregnancy for mother and fetus, and  the outcomes of  the babies and mothers. And 
lastly, to identify potential areas for improvement of outcome (defined as live healthy newborn, 
28 days after delivery).   
   
Methods
The project method  is a non-systematic literature review searching  the databases  PubMed, 
McMaster PLUS and Cochrane library. The search was limited to original articles and reviews 
published in English. 
Search words: diabetes, pregnan*, risk, future, treatment 
Findings
The risk factors in a pragnancy complicated by diabetes can be divided into different groups 
dependent on what time in the pregnancy it will lead to adverse outcomes and wheter it affects 
the mother or the baby. The complications known today are congenital malformations, death of 
fetus/infant, pre-eclampsia, preterm birth, macrosomia/large for gestational age baby, 
microvascular complications for mother and increased risk for developing diabetes and obesity 
later in life for mothers with gestational diabetes and offspring of parents with diabetes.  
 
Discussion
The complications for mother and child in pregnancy complicated by diabetes are mainly due to 
hyperglycemia. To predict to outcome of the pregnancy, one have to look at the degree of 
hyperglycemia, and at what time in the pregnancy this occures.It is obvious that to mainitain strict 
glycemic control is a major challenge for those involved.  
Conclusion
There are still many challenges in the pregnancy care of women with diabetes. The machanisms 
behind malformations, premature birth, preeclampsia and stillbirth are still not fully understood, 
but all of the challenges are related to suboptimal glycemic control in the pregnancy.
To promote healthy lifestyle pre-conceptionally is of outmost importance.    
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1.0 Abbreviations:
ADA: American Diabetes Association 
BNP: Brain Natriuretic Peptide
CEMACH: Confidential Enquiry into Mother and Child Health
EPO: Erythropoietin
FFA: Free Fatty Acids
GDM: Gestational Diabetes Mellitus 
HAPO: Hyperglycemia and Adverse Pregnancy Outcome study
HbA1c: Glycosylated hemoglobin
IADPSG: International Association of Diabetes and Pregnancy Study Groups
ISPAD: International Society for Pediatric and Adolecent Diabetes
LGA: Large for Gestational Age
MBRN: Medical Birth Registry of Norway
NCDR: Norwegian Childhood Diabetes Registry
NGF: Norwegian Society for Gynecology 
NICE: National Institute for health and Clinical Excellence
OGTT: Oral Glucose Tolerance Test 
PG: Plasma Glucose
PGDM: Pregestational Diabetes Mellitus
pro-BNP: pro-Brain Natriuretic Peptide
RDS: Respiratory Distress Syndrome
SGA: Small for Gestational Age 
T1D: Type 1 Diabetes
T2D: Type 2 Diabetes
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2.0 Litterature review
2.1 Background:
Insulin did not become available until the early 1920s, and most subjects with type 1 
diabetes (T1D) only lived a few months following the onset of the disease [1]. Diabetic 
ketoacidosis occured frequently, so maternal death occured commonly in pregnancies 
complicated by diabetes [2]. Not until the mid-1930s was the associtation of birth defects 
with diabetic pregnancy recognized, when use of insulin allowed the focus of clinical 
care to shift from maternal survival to neonatal outcome. 
The American pioneer in diabetes care of pregnant women, Pricilla White wrote in 1936, 
‘‘Congenital defects [including heart defects, gastrointestinal atresia, microcephaly, and 
achondroplasia] are beyond our therapeutic control and are, we believe, related to a 
disease which is genetic in origin’’ [3, 4]. In 1949 she wrote the article  ‘Pregnancy 
complicating diabetes’, published in American Journal of Medicine [3]. Here she first 
introduced the system later known as ‘White´s Classification Index of Diabetic 
Pregnancies’. She classified the patient after their level of risk determined by age at 
onset, duration, presence of atherosclerotic  vascular disease and renal complications. 
Later she added proliferative retinopathy as risk factor. The index was used to determine 
the outcome of the pregnancy and to give appropritate therapy and follow-up. This 
system became widely used throughout the world. 
As progression in diabetic care were made, new medical challenges arised, and a whole 
new patient group were born; the offspring of mothers with diabetes. The two major 
improvements that lead to this was the recognition  that improved control of maternal 
diabetes reduced morbidity and mortality of both the mother and the fetus. The other was 
the discovery of surfactant to reduce parinatal mortality from respiratory distress 
syndrome (RDS)[4]. Offspring of mothers with diabetes had increased risk of RDS both 
because there is an increased risk of pre-term birth and fetal insulin inhibits lung 
maturation [5]. 
RDS was largely treatable by the 1980s, and then major cause of neonatal mortality 
became congenital malformations [4]. As the malformations are to some extent caused by 
lack of glucose control in early pregnancy, the focus shifted again to pre-conceptional 
counselling and care. 
It is also a well known fact that thyroid dysfunction is prevalent amongst women with 
diabetes[6], and this may further complicate the outcome for the infant in the form of 
cerebral dysfunction.  
The increasing incidence of Type 2 Diabetes (T2D) is a major challenge for the future. In 
Oslo T2D leads to more congenital malformations and complications in pregnancy than 
T1D[7].
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Table 1: 
Modified White´s Classification Index of Diabetic Pregnancies:
There are 2 classes of gestational diabetes (diabetes which began during 
pregnancy):
• Class A1: gestational diabetes; diet controlled
• *Class A2: gestational diabetes; medication controlled
The second group of diabetes which existed before pregnancy can be split 
up into these classes:
• Class B: onset at age 20 or older or with duration of less than 10 
years
• Class C: onset at age 10-19 or duration of 10–19 years
• Class D: onset before age 10 or duration greater than 20 years
• Class E: overt diabetes mellitus with calcified pelvic vessels
• Class F: diabetic nephropathy
• *Class R: proliferative retinopathy
• *Class RF: retinopathy and nephropathy
• *Class H: ischemic heart disease
• *Class T: prior kidney transplant
An early age of onset or long-standing disease comes with greater risks.
* Classes added or futher subdivided after 1949.
White P: Pregnancy Complicating Diabetes. American Journal of Medicine 1949, Nov. 1949:609- 
616.
The aim of this project is to look at the obstetric situation for women living with diabetes 
today, with regard to the kind of preparations that have to be made prior to conception,  
major health risks during pregnancy for mother and fetus, and  the outcomes of  the 
babies and mothers. And lastly, to identify potential areas for improvement of outcome 
(defined as live healthy newborn, 28 days after delivery).   
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2.2 Methods
The project method  is a non-systematic literature review searching  the databases  
PubMed, McMaster PLUS and Cochrane library. The search was limited to original 
articles and reviews published in English. Search words: diabetes, pregnan*, risk, future, 
treatment. 
PubMed was  primarily used for the literature searches. When using the words ‘diabetes 
pregnancy risk’ and limited the search to links to full text, or free full text, humans, 
clinical trial, randomized controlled trial and English, 90 hits came up.  
To find illustrations google was a useful tool. 
The project is limited to deal with topics that are only/mostly found in pregnancies 
complicated with diabetes and their offspring, e.g. the topics that concern all newborns 
are let out, like breast feeding, mother-child bonding etc.  Discussion of which insulin 
analog or other medications are preferred or recommended have also deliberately been let 
out. 
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2.3 Epidemiology
According to WHO [8] 346 million people worldwide have diabetes, and more than 80% 
of people with diabetes live in low- or middle- income countries. It is expected that by 
2030 the number of people living with diabetes will double, and the increase in number 
will mainly affect developing countries [9].
In 2002, 1.4 % (776 out of 55 400) of women giving birth in Norway had diagnosed 
diabetes. Out of these 43%  (330/776)had pregestational diabetes. The incidence of T2D-
[7] and Gestational Diabetes Mellitus (GDM) is steadily increasing [10]. T2D is often 
undiagnosed at time of conception, and this increases the risk of diabetes related 
complications in pregnancy [7]. 
The reasons why we see more T2D in Norway today than previously is that ethnic 
Norwegian women are more overweight than before, and the number of  immigrants from 
areas where T2D has high prevalence has increased. Amongst pregnant women from 
Pakistan approxomately 30-50 % either has T2D or GDM [7].
 
8
2.4 Etiology and pathogenesis 
Diabetes is mainly divided into to major groups, T1D and T2D, but with several 
subgroups who more-or-less fall into one of the main groups. 
T1D is characterized by selective autoimmune destruction of the β-cells in the pancreatic 
Langerhans Islets, leading to hypoinsulinemia. T2D on the other hand is characterized by 
insulin resistance in body tissue, followed by uncompensated insulin production, a so-
called ‘relative insulin insufficiency’ [11].
Of all patients with diabetes, approximately 10% have T1D, and 80-90% have T2D. The 
obvious discrepancy between these numbers harbor an undiagnosed group with T2D.
Previously, T1D was referred to as ‘childhood onset diabetes’ and T2D as ‘adult onset 
diabetes’, but with the changes brought upon a modernized, technological society, we 
have developed into a more sedentary lifestyle with an energy surplus resulting in 
increased obesity and ‘lifestyle-diseases’. This has lead to a change in diabetic 
epidemiology and ethiology, with both an increase in the number of T2D cases, and 
younger age at the time of diagnosis. This has been called the ‘diabesity’ epidemic [12].
Even though the cause of the diseases are different, the long term complications of all 
types of diabetes are the same, with secondary affection of multiple organ systems, 
especially the kidneys, eyes, nerves and blood vessels [12].
2.4.1 Pathogenesis of Type 2 Diabetes Mellitus:
The exact pathogenesis of T2D is still unknown, but there is a consensus that it is caused 
by both environmental and genetic factors. There is no linkage between auto-immunity 
and T2D, but there has found several ‘diabetogenic‘ genes that seems to play a role, in 
addition to lifestyle factors, such as level of activity, dietary habits and obesity. The two 
main characteristics of T2D is: 1) decreased ability of peripheral tissue to respond to 
insulin (insulin resistance) and 2) unsatisfactory compensation of insulin production in 
response to the increased demand due to insulin resistance [12].  
Studies have shown an inverse correlation between free fatty acids (FFAs) and insulin 
resistance. Obese persons tend to have an abundance of FFAs, which in turn works as 
inhibitors of insulin signaling, resulting in decreased insulin sensitivity [12]. 
Adipose tissue is not only a storage organ, but it also has regulatory functions of the 
metabolism. Several adipocytokines that are involved in insulin sensitivity in peripheral 
tissues have been identified. Among these are leptin, adiponectin and resistin. 
Disturbances in these proteins are associated with insulin resistance and have been seen 
in obese persons [12].
2.4.2 Pathogenesis of gestational diabetes: 
GDM is diabetes diagnosed during pregnancy that is not clearly overt diabetes [13]. It 
usually develops in second trimester and resolves post partum, but follow up of the 
condition is crucial, to avoid missing an undiagnosed T2D [14].
In pregnancies, the normal physiologic response to increased concentration of pregnancy 
hormones - including estrogens and progestins- is a reduction of fasting blood glucose, 
increased adipose tissue, delay in gastric emptying and increased appetite. As the 
pregnancy goes on, the woman will develop a reduced insulin sensitivity, and blood 
glucose levels will increase again. As seen similarly in T2D, this state will demand an 
increase in β-cell production of insulin [14]. It is not fully understood why women who 
develop GDM are not able to increase their insulin production in response to the 
increased insulin resistance. There have been suggested disturbances in the insulin 
signaling cascade [15], dysfunctional insulin receptor [16] in addition to a genetic 
predisposition. 66 genes have been found upregulated in placentas of women with GDM 
[17]. 
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2.5 Diagnosing diabetes:
WHO has defined diabetes as a condition with fasting blood glucose ≥7.0 mmmol/L, or a 
2 hr plasma glucose ≥11.0 mmol/L. This definition was last reviewed November 2005. 
[18]. In 2011, WHO also recommended to test HbA1c for diagnosing diabetes mellitus. 
This test has shown to have a higher predictive value of  microvascular complications. 
HbA1c value at 6.5% is recommended as cut-off point, but a value below this does not 
rule out diabetes.  At the moment there is not sufficiently data to make any 
recommendations regarding HbA1c below 6.5% [19].
Table 2: Diagnostic criterias diabetes.
Diabetes Venous plasma Capillary blood
Fasting         >/= 7.0 mmol/L               >/= 6.1 mmol/L
120 mins oral glucose 
tolerance test (OGTT)
        >/= 11.1 mmol/L              >/= 11.1mmol/Ll
HbA1c         >/= 6.5%               >/= 6.5%
WHO: Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia- 
Report of a WHO/IDF consultation. 2006.
Table 3: Diagnostic criterias impaired glucose tolerance.
Impaired glucose 
tolerance
Venous plasma Caillary blood
120 mins oral glucose 
tolerance test (OGTT)
>/= 7.8 - <11.1 mmol/L >/= 7.8  - <11.1 mmol/L
WHO: Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia- 
Report of a WHO/IDF consultation. 2006.
The OGTT test should be performed as described by WHO [18], using a glucose load 
containing the equivalent of 75 g glucose dissolved in water or 1,75 g/kg of body weight 
to a maximum of 65 g. 
To further distinguish the diabetes between type 1 and type 2 it is advised to measure 
diabetes associated auto-antibodies [20].
In Denmark they recommend srceening for GDM early in pregnancy if the mother  has 
high risk of GDM (previously GDM, glucoseuria and must have two out of three of: 
family history of diabetes, BMI > 27, previous birt to macrosmic or LGA baby) [21]. In 
28th -32nd gestational week they screen women with one out of the three risk factors 
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above, or women who were screened early in pregnancy, but then not diagnosed with 
diabetes [21].   
The recommendations for screening in Norway is a bit different from Denmark since they 
divide the women with high risk of GDM into three different groups. 
Table 4: Indications for glucose screening in pregnancy- Norway
Group A 1. Previously gestational diabetes mellitus.
2. Family history of type 1- or type 2- diabetes in 
first degree relative.
3. Immigrants, especially from North Africa and 
Indian subcontinent, others by consideration.
4. Age >35.
5. Obese /overweight (BMI >27).
As early in the pregnancy as 
possible. To be repeted in week 
28- 30 if negative test the first 
time.
Group B Manifest glucoseuria, especially if it is reproducable 
and without overt explanation
When glucoseuria is first 
detected. If first oral glucose 
tolerance test (OGTT) is 
negative, and glucoseuria is 
again detected, repeat test in 
4-6 weeks (or sooner if in last 
trimester).
Group C Development of polyhydramnion and /or rapid fetal 
growth in current pregnancy. Previous birth to large 
for gestational age baby  or (>4500 g) or fasting 
blood sugar between 6.1 and 7.0 mmol/l. 
OGTT by consideration. Also 
for women with previous 
congenital malformations or 
stillbirths. 
Modified from Norwegian Society for Gynecology (http://legeforeningen.no/Fagmed/
Norsk-gynekologisk-forening/Veiledere/veileder-i-fodselshjelp-2008/kapittel-8-diabetes-
i-svangerskapet/)
The Hyperglycemia and Adverse Pregnancy Outcome study (HAPO) [22] showed a 
strong association between maternal hyperglycemia and adverse pregnancy outcomes, 
even in the subclinical ranges. On behalf of this, the International Association of Diabetes 
and Pregnancy Study Groups (IADPSG) [23] has suggested new criterias for GDM. They 
are somehow ‘stricter’ with  fasting plama glucose (FPG) ≥ 5.1 mmol/l or 2 hrs plasma 
glucose after oral glucose tolerance test (OGTT) ≥8.5 mmol/l.  
The WHO criterias are still being used in Norway, but in the Stork Grorud project they 
diagnosed the study participants both according to the WHO and the IADPSG criterias. 
Not suprisingly, the prevalence differed, with 13% with WHO and 31.5% with modified 
IADPSG criterias [24]. They also saw that this increase in prevalence was strongly 
associated with South Asian origin and prepregnant overweight.  
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2.5.1 Risk factors of developing gestational diabetes:
GDM is complex, and there have been found many risk factors for developing the 
condition. So far these factors are known:
• previous gestational diabetes
• obesity (BMI >30) or overweight (BMI 25-29)
• macrosomic infant in previous pregnancy
• suspected glucose intolerance in previous pregnancy  
• glucosuria
• strong first degree family history of T2D or gestational diabetes
• history of unexplained fetal demise
• >24 years old
Women older than 24 years of age have a 7-10 times higher risk of developing gestational 
diabetes than younger women. Studies also show that obese women have more than 3-
fold increased risk of gestaional diabetes compared with non-obese women [14].
The STORK Groruddalen study also showed that genetics is an important factor in 
developing GDM [24].   
Studies have shown that prenatal exercise can delay or prevent the development of GDM, 
and exercise during pregnancy can prevent complications to the baby [25]. Zhang et al. 
found that women who did not do any vigorous activity and spent 20 hrs or more each 
week watching television had a higher risk of developing GDM than women who did 
physical activity and spent less than 2 hrs each week watching television [25]. 
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2.6 Diabetes and risk factors in pregnancy
Well-known complications and adverse outcomes of pregnancies complicated by diabetes 
are pre-eclampsia, preterm birth, fetal hypoxia, perinatal death, stilldeath, infant death, 
non-spontaneous start of labour, increased  rate of caesarean sections, macrosomia or 
large for gestational age [14, 26-30]. Later in life the offspring of parents with T1D has 
an increased risk of developing T1D, seven fold increase if the mother has the condition 
[31, 32], and as much as 21 fold increase if it comes from the father [33]. GDM increases 
the risk of childhood obesity, T2D and metabolic syndrome at a very early age for the 
offspring [34]. 
2.6.1 Congenital malformations due to hyperglycemia
Several studies have shown an association between diabetes and congenital 
malformations in the offspring. The most commonly seen are neural tube- and 
cardiovascular defects [35-37]. Since these organ systems are developed within the eight 
gestational week, the influence of the maternal diabetes happens in this first period of the 
pregnancy. By this time, many women are not even aware of the fact that they are 
pregnant, so this reinforces the need for pre-conceptional diabetic care. This applies to 
women with pregestational diabetes, since GDM usually develops in second or third 
trimester [14], when the organogenesis is already completed.
Many recent studies have shown a link between pre-pregnancy obesity and congenital 
malformations [38-40]. This may be because many patients with T2D are undiagnosed, 
and are not discovered until later in pregnancy or later in life [41]. Since the prevalence 
of T2D is rising, it is expected to see an increase in diabetes associated congenital 
malformations [4]. This is a massive challenge for the health care, and rises the question 
of whether it is indicated to screen larger groups for diabetes.
Eidem et al. [30] conducted  a large population based study where they linked the 
Medical Birth Registry of Norway (MBRN) and the Norwegian Childhood Diabetes 
Registry (NCDR). They looked at all births in Norway from 1999 to 2004 (N=350 961). 
Of these were 1583 births by women with pregestational T1D. The prevalence of 
congenital malformations in the diabetes group were 5.7% compared to 2.9% in the rest 
of the population. The most commonly seen malformation in this study was affects of the 
cardiovascular system; it was seen three times more often than in the background 
population. 
Eidem et al. [30] reported no association between duration of diabetes and adverse 
outcome after adjusting for maternal age and year of birth. However, they did see that the 
T1D group was not heterogeneous, and the risk was different in different socioeconomic 
groups. The women with college or university education and T1D ‘had a borderline 
significant lower proportion compared to those with high school education only (adjusted 
odds ratio 0.58, 95% CI 0.31-1.07, global p-value for education level: 0.09)’ [30]. 
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‘Women in the diabetes group who reported smoking, had an adjusted odds ratio for 
malformations of 1.36 (0.79-2.3) compared with those who did not report smoking’ [30].
In this context it is interesting to notice that more women in the diabetes group reported 
smoking during pregnancy, and fewer had college- or university degrees than in the 
background population.
The Confidential Enquiry into Maternal and Child Health (CEMACH) [42] from UK had 
similar findings. The prevalence of congenital malformations were doubled compared 
with the background population (41.8/1000 compared with 21/1000).
A cohort study done by Temple et al. in 2006 [43] had amazing results concerning 
prepregnancy care in women with T1D. The women in the prepregnancy care had lower 
HbA1c before conception and the two first trimesters, and they found fewer congenital 
malformations, stillbirths, neonatal births and very premature deliveries. They did not, 
however, see any differences concerning pre-eclampsia, glycemic control in late 
pregnancy, macrosomia and caesarean section. 
Several studies report hypertrophic cardiomyopathy in newborn infants of mothers with 
T1D [44-46]. Most of these changes were asymphtomatic and disappeared within the first  
six months of life, but some lead to severe morbidity and mortality. 
Usually the majority of the infants only need supportive care, and postnatal 
echocardiography is not required unless there are clinical signs [47]. 
During labour it was found that ST depression occurred more frequently in pregnancies 
complicated by diabetes, and especially in pregnancies with poor glycemic control in late 
pregnancy [48]. 
Brain natriuretic peptide (BNP) is a peptide produced in the cardiac muscle if put under 
mechanical strech, and it works in the regulation of extracellular volume and blood 
pressure by increasing natriuresis, and inhibiting the renin-angiotensin-aldestorone axis. 
In the fetus it works as a vasoldilator in the placental circulation and probably has 
protective autocrine effects by inhibiting fibrosis and hypertrophy of the heart [49]. 
Increased plasma concentrations of BNP and proBNP are seen in patients with heart 
failure, children with congenital heart disease and newborns with severe fetal distress [50, 
51].
It has been seen higher median plasme proBNP concentrations in offspring of women 
with suboptimal glycemic control (HbA1c >6.2%) compared with offspring of health 
women [26]. 
A study by Russels et al. [100] also reported increased levels of BNP and proBNP in the 
umbilical cord blood of offspring from women with T1D and the increase was mostly 
marked in infants of women with poor glycemic control in early pregnancy. 
Another complication that can bee seen is placental insufficiency, leading to intrauterine 
growth restriction and a baby who is small for gestational age (SGA) [54].
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This has major implications especially if the baby is born pre-term. The SGA baby is 
known to have increased risk of neurodevelopmental sequelae [55] and persistent 
hypoglycemia postnatally. However, studies have shown that this outcome may be 
prevented by well-controlled diabetes in pregnancy [56, 57].  
2.6.2 Death of fetus/ infant:
In different literature there are many different terms to describe death of a fetus or child, 
such as fetal death, fetal demise, in utero loss, intrauterine (fetal) death, stillbirth, (early) 
neonatal death, perinatal death and infant death. Therefore there is a need to clarify the 
understanding of the terms used in the following section.    
Table 5: Definitions of terms to describe death of a fetus or child
Definition
Stillbirth In utero loss delivering after 24 completed weeks of gestation
Perinatal death Stillbirth or death during the first 7 days of life 
Early neonatal death Death of a live born infant during the first 7 days of life
Neonatal death Death of a live born infant during the first 28 days of life
Infant death Death during the first year of life
Adapted from Eidem 2011 and CEMACH.
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Table 6: Comparing data on pregnancy outcome, studies from Norway and Denmark 
Eidems study 1) Jensen´s study 2)
Study period 1985-2004 1993-1999
Country of origin Norway   (nationwide) Denmark (selected centres)
Participants (n) 1 161 092 70 089
Diagnosis T1D T1D
Participants with diabetes (n) 1 307 1218
Risk of perinatal death and 
stillbirth 
x3* x 4*
(Perinatal mortality only)
Risk of stillbirth - x 5*
Risk of infant death x2* -
Risk of stillbirth and infant 
death
x3* -
OR stillbirth 1.8 (95% CI 1.2-2-8) -
OR perinatal death 1.6 (95% CI 1.1-2.3) -
OR stillbirth or infant death 1.6 (95% CI 1.1-2.2) -
(* compared with background population.)
1) Eidem et al. Diabetologia 2011: Perinatal and infant mortality in term and preterm births 
among    women with type 1 diabetes.  
2) Jensen et al. Diabetes Care 2004: Outcomes in type 1 diabetic pregnancies. 
 
As we can see from the table above, Eidem [30] found a lower risk of perinatal death and 
stillbirth compared with Jensen´s study [101]. This might be due to differences in the 
population sizes and selection of centres included in the Danish study. Another unknown 
factor which may play a role in the outcome, is the potential event of undiagnosed T2D in 
the background population. The screening for diabetes in Norway is not as systematic as 
in other comparable countries. 
The different results may also reflect different national differences as genetics, standard 
of health care, socioeconomic status etc. 
Both Eidem [30] and Jensen [101] confirmed that preterm deliveries occur much more 
frequently in pregnancies complicated by diabetes, but most interestingly, Eidems study 
adjusted the numbers for perinatal death into pre-term and term deliveries. And even 
though pre-term delivery plays a huge role in perinatal deaths, their findings showed that 
the excess rate of perinatal death was confined to the term T1D group. There was an 
unsignificant difference in mortality rates in preterm deliveries in the two groups. 
Eidems study [30] found that mothers of T1D were on average slightly younger at 
delivery and had slightly lower parity than those without T1D, and they were more often 
of European origin. Other differences were minor. Of the women with T1D, almost 20% 
were registered with pre-eclampsia, 26% delivered preterm, out of which 42% were 
spontaneous pre-term deliveries. Median gestational age for the women with T1D were 
38.4 weeks compared with 40.2 weeks in the background population.
Of the women who delivered pre-term, there were no differences in the risk of perinatal 
death between women with T1D and the background population. However, in the group 
of women with T1D who delivered spontaneously at term there was a five times higher 
risk of perinatal death than in the background population. 
Another interesting finding of Eidem et al. [30] were that the offspring of women with 
T1D had a significantly higher risk of death during the first year of life compared with 
the background population. 
Another Danish study reported that 50% of stillbirths were unexplained, but most of these 
had suboptimal glycemic control in late pregnancy, many also had problems with diabetic 
nephropathy, smoking and low social status [58]. 
The explained stillbirths were pregnancies complicated by intrauterine growth restriction, 
pre-eclampsia, umbilical cord problems, acute asphyxia, placental abruption, intrauterine 
infection, congenital malformations or maternal ketoacidosis. Many were also related to 
diabetes, for example, due to congenital malformations, diabetic nephropathy and 
matenal diabetic ketoacidosis [26]. 
Other characteristics of pregnancies ending with a stillbirth were smoking and a low 
social status [58].
 
There has been suggested that oxidative stress could play a role in pre-eclampsia, and that 
the supplemetnation of vitamin C and E could reduce the insidence of this serious 
disorder [59, 60]. Randomised placebo-controlled trials [59, 60] have been done to 
further investigate this, and the women were either given 1000 mg vitamin C and 400 IU 
vitamin E daily, or a placebo. The supplementation did not prevent pre-eclampsia in 
women with increased clinical risk factors for pre-eclampsia[59] or in women with T1D 
[60].
In pregnancies with GDM there is no increased risk of perinatal death or stillbirth, but the 
incidense of macrosomia and large for gestational age (LGA) is much higher than in the 
general population [61].  Later in life, the offspring has an increased risk of developing 
T2D [14].
18
2.6.3 Sum up of outcomes of risk factors
Table 7: Maternal hyperglycemia in different stages of the pregnancy represents risk 
factors for different pregnancy outcome, divided in pregestational diabetes and 
gestational diabetes 
Hyperglycemia Risk factor Pregestational 
diabetes 
Gestational 
diabetes
First trimester Congenital 
malformations
           *
Third trimester Pre-eclampsia            *
Third trimester Preterm birth            *
Third trimester Perinatal death/
stillbirth/
infant death
           *
Third trimester Macrosomia/Large 
for gestational age 
           *             *
*: increased risk
2.6.4 Teratogenity and fetal effects of hyperglycemia:
Insulin is not transported across the placenta [4, 28], and the fetal pancreatic beta cells are 
not present until 10th gestational week [62], so it can not be responsible for any 
congenital malformations associated with pregestational diabetes. The teratogenic effect 
of hyperglycemia, on the other hand, has been proved by animal studies [63]. In the first 
trimester the natural physiologic response of pregnancy is a hypoglycemic state in 
healthy pregnancies, the potential teratogenic effect of glucose (hyperglycemia) applies to 
women with pregestational diabetes.  
Hypoglycemic episodes have proven embryotoxic in animal studies, but this has not been 
seen in humans [64, 65].
The fetal effect of maternal hyperglycemia has been explained in the Pedersen hypothesis 
[22, 26]. It states that maternal hyperglycemia gives a fetal hyperglycemia, which causes 
a fetal hyperinsulinemia through overstimulation of the fetal beta-cells. Since insulin is 
an anabolic hormone this will stimulate protein, lipid and glycogen [28], and cause 
increased fetal growth, more adipose tissue and increased hepatic glycogen storage [26]. 
This increase in metabolism will be manifest as LGA  or macrosomia and it may cause 
relative decrease in arterial oxygen content [26]. The association between hyperglycemia 
and hyperinsulinemia and hypoxia have been seen in animal studies [26]. 
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Figure 1: The fetal effect of maternal hyperglycemia explained by  The Pedersen 
Hypothesis: 
Michael Varner, lecture on Gestational Diabetes, University of Utah Health Services 
Centre, [66])
Pregnancies complicated by diabetes, pre-eclampsia and fetuses small or large for 
gestational age show an increase in stillbirths and fetuses with sign of hypoxia, acidosis, 
increased plasma and amniotic fluid values of erythropeietin (EPO) [67, 68]. It is known 
that the major stimulus of EPO is hypoxia. There have been described increased levels of 
amniotic values of EPO prior to stillbirth in pregnancies complicated by diabetes [69]. 
After birth the infant will no longer receive placental nutrition, and fully depend on its 
own glucose- and ketone bodies- production. The Pederesen hypothesis indicate how the 
baby is at risk of hyperinsulinism, and  therefore will have little glucose available as fuel.  
The baby will be in a state of hepatic glycogen- and lipid production, and will not 
produce ketone bodies [28]. This state of hypoketonaemic hypoglycemia is potentially 
neurotoxic, but there is no evidence that it will occur without clinical signs [28]. Since 
there are no clinical studies with sufficient evidence to prove the link between neonatal 
hypoglycemia and brain injury, it has not been possible to provide evidence based 
guidelines [28]. However,  guidelines for the prevention and management of neonatal 
hypoglycemia due to maternal diabetes have been developed, and are being used [70]. 
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Another response of the fetus to the maternal hyperglycemia is increased growth, either 
classified as macrosomia or LGA [28]. These are not interchangeable terms. Macrosomia 
means a baby with a birth weight higher what was genetically determined, and it is 
defined as a birth weight above the 90th percentile. This usually means increased growth 
of abdominal fat and organs. , LGA refers to a fetus or infant who is larger than expected 
for the age and gender or with a birth weight above the 90th percentile.
The measurement is based on the estimated gestational age of the fetus or infant, 
compared with what is considered normal height, weight, head size, and developmental 
level for a fetus or infant of the same age and gender [28]. 
In women with GDM it has been shown that increased mean maternal glucose 
concentration is associated with increased neonatal birthweight [54], and elevated insulin 
concentrations in fetal blood and amniotic fluid is associated with macrosomia [71, 72].
The two terms are often confused, but it is macrosomy and organomegaly that is mainly 
associated with diabetes in pregnancy [28]. 
Giving birth to a baby with macrosomia or LGA may lead to complications, such as 
shoulder dystocia, obstructed labour, perinatal hypoxia-ischemia and birth related injuries 
in both mother and baby [14, 28]. To avoid complications in labour, it is often prefered to 
deliver by ceasarean section when a macrosomic or LGA baby is expected [14]. 
National cohort studies in the UK and Netherlands found that the rate of ceasarean 
section in women with diabetes (43%  and 44%) was more than doubled compared with 
the rest of the UK population (20%) [28]. But use of caesarean section involves trauma to 
the mother, and the cost vs. benefits have to be taken into consideration when electing 
mode of deliviery [28]. 
The Hyperglycemia and Adverse Pregnancy Outcome [22] study from 2008 found that 
even subclinical hyperglycemia was significantly associated with LGA births.
Clausen et al. concluded in their study from 2008 [73] that a hyperglycemic intrauterine 
enviroment is involved in the pathogenesis of T2D or pre-diabetes in the adult offspring 
of mothers who had diet treated GDM or T1D during pregnancy. The study was Danish 
and most of the participants were of Caucasian origin. 
2.6.5 Maternal effects 
It is more difficult to maintain stable blood sugar levels during pregnancy because of the 
change in metabolism and the influence of the hormones [14]. This fluctuation in blood 
glucose may deteriorate microvascular complications [27], and it is therefore very 
important that the woman with pregestational diabetes  will seek medical help and 
intervention before getting pregnant. 
To optimize the outcome for the fetus, it is important that the blood glucose is within the 
desired range, and this may demand upjusting the insulin doses. However, a sudden 
improvement in glycemic control with increased insulin treatment, may temporarily 
deteriorate retinopathy [74, 75]. It has been shown that poor glycemic control and 
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hypertention in first trimester increases the risk of progression [76]. In addition to 
maintaining stable blood sugars, the retinas needs to be investigated before and during 
pregnancy, and if necessary laser treatment can be given [27].
The major obstacle to achieving tight glycemic control in pregnant women is the risk of 
hypoglycemia. The risk is highest in first trimester, especially between 8th and 16th 
gestational week [77-79]. The risk is as much as five times higher than the year before 
getting pregnant [78]. Hypoglycemia may lead to severe incidents, like hypoglycemic 
coma [80], traffic accidents [77] and death [81]. To avoid hypoglycemia continous blood 
glucose monitoring is recommended in pregnancy [82].  
New-onset hypertension or pre-eclampsia are relatively common and potentially serious 
complications of pregnancy. The incidence of hypertension in women who have diabetes 
is 15-20 % compared with 5% in the background population [83, 84]. 
Several factors contribute in the developement of hypertension, and it is unclear what 
comes first. Several observational studies have shown a link between the developement 
of hypertension in pregnancy hyperinsulinemia and insulin resistance [85-87]. Insulin 
does promote weight gain, which may increase blood pressure [27]. However, there has 
not been found that changes in blood pressure is associated with the use of exogenous 
insulin [27]. 
There seems to be a ´vicous cycle´ between hypertension and nephropathy where the 
presence of one of them both increases the risk of and deteriorate the presence of the 
other [88, 89]. The development of nephropathy in patients with diabetes heralds an 
increased risk of mortality not only from end-stage renal failure, but also from 
cardiovascular causes [90]. 
The presence of microalbuminuria or nephropathy in early pregnancy is associated with 
increased risk of preterm delivery, mainly due to pre-eclampsia [91].
For women with GDM the main long term concern is the increased risk for developing 
metabolic syndrome and T2D. A review  study by Vohr and Boney in 2008 [92]found 
strong evidence that women with GDM and obesity have a much higher risk of 
developing metabolic syndrome than women without GDM.
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2.7 Treatment and standard of care
All the litterature reviewed for this project emphasized the importance of planned 
pregnancy for women with diabetes. The subject must be brought up in relatively early 
age, and the women must use a safe contraception method. The National Clinical 
Guidelines [7] from The Norwegian Directorate of Health  recommends that HbA1c 
should be <7% by the time on conception and through first trimester. In second and third 
trimester HbA1c sholud be below 5.8%. Keep in mind then that from second trimester 
this is normally 1%-point lower than when not pregnant. 
The Norwegian Directorate of Health: Guidelines for planned pregnancy for women with 
diabetes [7]:
• Consider referal to specialist health care if preconseptional plasma glucose (PG) is not 
achieved in desired range. During pregnancy, all women with diabetes should be 
followed by units experienced in the field.
• Motivate to achieve optimal regulation of diabetes.
• Discontinue per oral antidiabetic treatment if this is being used. Metformin may be 
used. Consider starting insulin treatment. 
• Discontinue statins, ACE- inhibitors and angiotensin II- antagonists.
• Optimize blood glucose control. Refer to dietician if needed.
• If hypertension is present she must be refered to specialist health care.
• Motivate to stop smoking
• Consider refering to ophthalmolgist.
• Intensify patient education.
• Start taking folic acid and omega-3 fish liver oil daily. 
During pregnancy the aim is to keep PG between 4 and 8 mmol/l thoughout the whole 
day and night. 
Women diagnosed with GDM are given diet and excercise counseling. If needed they 
also have to start continous blood glucose monitoring and insulin therapy. They are 
generally given the same advices as other pregnant women when it comes to daily caloric 
intake, vitamin supplements and excersise. All pregnant women in Norway are 
recommended to take 400 µg folic acid and omega-3 fish oil daily [93]. 
It is recommended to do an OGTT on women with GDM 6-12 weeks after birth, since 
not all GDM resolve after birth but remains as T2D [7].
Mathiesen´s recommendations are in concurrence with the Norwegian. During pregnancy 
she recommends that preprandial PG should be between 3.5 and 5.9 mmol/l, and 
postpranial PG should be between 3.5 and 7.8 mmol/l [27]. 
To avoid hypoglycemia is a challenge, so insulin dose should be reduced at around 8-16 
week, and steady increased again from 16th week until delivery [27]. In second and third 
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trimester the American Diabetes Association (ADA) has recommended an HbA1c <6% 
[94].
The Norwegian Society for Gynecology [10] recommends that if HbA1c is >8 % 
periconceptional, the women should be offered early ultrasound (at about 12th gestational 
week) in concern of congenital malformations. 
In Copenhagen, Denmark, women with pregestational diabetes are offered antenatal 
ultrasound examination of fetal growth rate at 28, 34 and 37 weeks, once weekly non-
stress testing from 33 to 34 weeks and kick counting from 28th week until delivery [26]. 
This strategy, in addition to strict glycemic control has given the result that the 
stillbirthrate in the diabetes group is closer to the background population [26].  
There is no international consencus regarding the recommendations for when to initiate 
time of delivery in pregnancies complicated by diabetes. The National Institute for Health 
and Clinical Excellence (NICE) [95] says they should be offered elective birth after 38 
completed weeks, ADA states that ‘well-monitored diabetic women achieving excellent 
glycaemic control without obstetrical complications can await spontaneous labour up to 
39-40 weeks gestation´ [94].The recommendation by the Norwegian Society for 
Gynecology (NGF) for women treated with insulin is induction around term, others 
should be considered individually. Ceasarean section should be used in obstetric 
complications and if serious vascular, kidney or eye-complications [10].    
After delivery it is very important that the newborn will be monitored closely, especially 
concerning the glucose levels, since it is at high risk of  hypoketonaemic hypoglycemia 
[27, 28].
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3.0 Discussion
Women in Norway with pregestational diabetes are being closely followed up, and given  
pregestaional care and information. This is also the group with highest risk of adverse 
outcome, in the form of hypoglycemic epiodes, congenital malformations in infant, 
preterm deliveries, pre-eclampsia, stillbirth, perinatal death and infant death and 
macrosomia and LGA. In addition to complications directly connected with pregnancy, 
the mother has increased risk of microvascular complications due to the general 
hyperglycemia. But despite this awareness and massive health care service, the incidence 
of adverse outcome in pregnancies complicated by diabetes is still high. 
Since both T2D and GDM is on the rise, the situation is not expected to change in the 
future, unless changes are being made. 
Eidems study on congenital malformations found that the risk of congenital 
malformations were doubled and the risk of cardiovascular malformations were tripled in 
the T1D group compared with the background population. Their findings indicated that 
the women are not satisfactory regulated, and improvements can be made.. 
The underlying mechanisms to the congenital malformations are not fully known, but  
hyperglycemia induced oxidative stress and glyco-oxidative mechanisms have been 
suggested to play an important role [30]. Cigarette smoking and socioeconomic 
background as contributing risk factors to congenital malformations should also be 
investigated further. 
As strict glycemic control before conception and in first trimester will reduce the risk of 
congenital malformations, it is likely that glycemic control in second and third triemster 
will reduce the rate of stillbirths, perinatal death, complicated deliveries and caesarean 
sections, macrosmia and LGA. 
It is also advisable to motivate the women to refrain from smoking during pregnancy.
Antihypertensive treatment in pregnancy is complicated as some of the most commonly 
used medications are contraindicated in pregnancy. However,  there is strong evidence 
that proper hypertensive management in women with microalbuminuria or diabetic 
nephropathy will reduce the risk of pre-eclampsia and pre-term delivery [91, 96].
The main challenge for improving the outcome for pregnancies complicated by diabetes 
is to maintain plasma glucose within desired range. There exists a massive amount of 
litterature supporting the benefit of avoiding hypoglycemia, but very little has been said 
about the reasons why this is not achieved in all women. Is it a motivational problem in 
the women with diabetes? Are the health service providers not putting enough emphasis 
on the importance of maintaining strict glucose control, or is it a communicative 
problem? There would be helpful to investigate this problem more, and come up with 
strategies or guidelines to motivate these women even more.
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In many countries -another obstacle to maintain strict glucose control is the cost. Not 
only does it demand a lot of effort from all of the implied persons, but it also demands a 
lot of equipment and medications. This should however not be the situation in Norway as 
treatment of diabetes is free for the patient. All medical expences related to the disease 
are paid by the government.
There is also an ethical side that arises with parts of the treatment today. Many clinics 
offer the women early ultrasound examination [26]. This is in concern of congenital 
malformations. If a malformation is detected on early ultrasound, the next step is for the 
woman to choose between an elective abortion or to let the pregnancy move on and 
deliver the baby.
In Norway today, there is an ongoing debate on whether early ultrasound in pregnancy 
should be offered by the public healthcare to all women. One of the arguments against 
this proposal is that we might get  a ‘selective society’ where there is no room for people 
with disabilities. The choice of raising a child with malformations will always be a 
difficult  decision for the woman.
There  has been suggested new criterias for diagnosing GDM [23], and as seen in    
Jenum´s study from 2012 [24], this will lead to a significant increase in the prevalence of 
GDM. The benefits of using the new criterias are to prevent macrosomia in offspirng, 
childhood overweight and metabolic factors that may increase the risk of cardiovascular 
disease [23]. On the other hand, to recommend this new standard will have a large impact 
on the health care budget. When considered the poor reproducibility of the OGT-test 
[97-99], the cost vs. benefit is large. Jenum suggests that population- based strategies to 
prevent overweight and improve living condition earlier in life may be more beneficial. 
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4.0 Conclusion
 
There are still many challenges in the pregnancy care of women with diabetes. One is to 
make sure that women with already diagnosed diabetes (T1D and T2D) are taken care of 
in prenatal diabetic clinics  which are updated on national and international treatment 
guidelines. This diabetes care has to include pre-pregnancy care. The second challenge 
will be to find the women with unknown T2D and the women in risk of developing 
GDM.
  
The main goal will then be to achieve a  glycemic control as close to normal as possible 
while avoiding severe hypoglycemia as well as frequent moderate hypoglycemia. To 
achieve this goal is  a huge challenge that has not yet been met . Little have been 
documented in concern to motivational interviews and there might bee  a potential for 
improvement here. Also the technology for glucose monitoring and insulin administration 
available today may need evaluating for potential improvements.  
Hypertension in pregnancy is common, but still not optimally treated. The impacts of 
hypertension are massive, and this must be a field of improvement in the future.  
The outmost desirable scenario for the future would be to reduce the insidence of new 
onset T2D and GDM to a minimum. Some of the triggering factors are well known, as 
overweight/obsesity and sedate lifestyle. This also triggers other diseases, so there is no 
doubt that a general alteration from sedate to active lifestyle would be beneficial for the 
whole society, and would be a very cost-efficient initiative. 
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